New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - lenalidomide 10mg - capsule - 10 mg - active: lenalidomide 10mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   indigo carmine iron oxide black iron oxide yellow   microcrystalline cellulose sodium stearyl fumarate starch tekprint black sw-9008 titanium dioxide   - multiple myeloma (mm) " the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. " the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. " in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - lenalidomide 15mg - capsule - 15 mg - active: lenalidomide 15mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   microcrystalline cellulose opacode red s-1-15094 sodium stearyl fumarate starch titanium dioxide   - multiple myeloma (mm) " the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. " the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. " in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - lenalidomide 2.5mg - capsule - 2.5 mg - active: lenalidomide 2.5mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   indigo carmine iron oxide yellow microcrystalline cellulose sodium stearyl fumarate starch tekprint black sw-9008 titanium dioxide   - multiple myeloma (mm) " the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. " the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. " in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - lenalidomide 20mg - capsule - 20 mg - active: lenalidomide 20mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   indigo carmine iron oxide yellow microcrystalline cellulose opacode red s-1-15095 sodium stearyl fumarate starch titanium dioxide   - multiple myeloma (mm) " the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. " the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. " in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - lenalidomide 25mg - capsule - 25 mg - active: lenalidomide 25mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   microcrystalline cellulose sodium stearyl fumarate starch tekprint black sw-9008 titanium dioxide   - multiple myeloma (mm) " the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. " the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. " in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - lenalidomide 5mg - capsule - 5 mg - active: lenalidomide 5mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   microcrystalline cellulose sodium stearyl fumarate starch tekprint black sw-9008 titanium dioxide   - multiple myeloma (mm) " the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. " the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. " in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - lenalidomide 7.5mg - capsule - 7.5 mg - active: lenalidomide 7.5mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   iron oxide black iron oxide yellow microcrystalline cellulose sodium stearyl fumarate starch tekprint black sw-9008 titanium dioxide   - multiple myeloma (mm) " the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. " the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. " in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - solifenacin succinate 10mg;   - film coated tablet - 10 mg - active: solifenacin succinate 10mg   excipient: hypromellose   iron oxide red iron oxide yellow lactose magnesium stearate maize starch propylene glycol purified talc titanium dioxide - solifenacin viatris is indicated for the treatment of unstable bladder with symptoms of increased urinary urgency, frequent microurination, and/or urge incontinence.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - solifenacin succinate 5mg;   - film coated tablet - 5 mg - active: solifenacin succinate 5mg   excipient: hypromellose   iron oxide yellow lactose magnesium stearate maize starch propylene glycol purified talc titanium dioxide - solifenacin viatris is indicated for the treatment of unstable bladder with symptoms of increased urinary urgency, frequent microurination, and/or urge incontinence.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

viatris limited - zoledronic acid monohydrate 0.8528 mg/ml equivalent to zoledronic acid 0.8 mg/ml;   - concentrate for infusion - 4 mg/5ml - active: zoledronic acid monohydrate 0.8528 mg/ml equivalent to zoledronic acid 0.8 mg/ml   excipient: hydrochloric acid sodium citrate sodium hydroxide water for injection - · treatment of tumour-induced hypercalcaemia.